Abstracts
3427228
(#57) Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: Assessment of Treatment Patterns and Acute Care Events in Patients With Schizophrenia or Bipolar I Disorder
Abstract: Introduction: Combined olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. The objective of this study was to compare treatment patterns and acute care events in patients with schizophrenia or bipolar I disorder (BD-I) initiating OLZ/SAM versus olanzapine.
Methods: This claims analysis used Komodo Healthcare Map data (10/18/2020-12/31/2023). Medicaid-insured adults with schizophrenia or BD-I with ≥1 OLZ/SAM or olanzapine claim were eligible; OLZ/SAM claims were prioritized over olanzapine claims to set the index date. Patients were propensity score matched 1:1 on baseline demographic/clinical variables between the OLZ/SAM and olanzapine cohorts. Treatment patterns (adherence, persistence, discontinuation), inpatient (IP) admissions, and emergency department (ED) visits (all cause, mental health related, or disease related [used as proxies for relapse]) were compared between cohorts during 12-month follow-up.
Results: After matching, 1614 patients with schizophrenia (OLZ/SAM, n=807; olanzapine, n=807) and 1008 with BD-I (OLZ/SAM, n=504; olanzapine, n=504) were included across both treatment cohorts. In both cohorts, OLZ/SAM was associated with significantly higher adherence, longer persistence, and lower discontinuation rates versus olanzapine. OLZ/SAM was associated with significantly lower likelihood of ≥1 all-cause, mental health-related, or disease-related IP admission (odds ratio [OR] ranges, schizophrenia: 0.52-0.59; BD-I: 0.52-0.58) or ED visit (OR ranges, schizophrenia: 0.47-0.54; BD-I: 0.62-0.74).
Conclusions: OLZ/SAM treatment offers real-world effectiveness benefits over olanzapine, with favorable treatment patterns and significantly lower likelihood of acute care events. Significantly lower likelihood of disease-related acute care events suggests lower relapse risk with OLZ/SAM treatment.
Short Description: This claims analysis compared combined olanzapine and samidorphan (OLZ/SAM) with olanzapine in Medicaid‑insured adults with schizophrenia or bipolar I disorder. OLZ/SAM was associated with higher adherence and persistence and lower discontinuation versus olanzapine and significantly fewer inpatient admissions and emergency department visits across all‑cause, mental health-related, and disease‑related categories. OLZ/SAM treatment offers meaningful real-world effectiveness benefits over olanzapine, as observed by favorable treatment patterns and significantly lower likelihood of acute care events.
Name of Sponsoring Organization(s): This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
Methods: This claims analysis used Komodo Healthcare Map data (10/18/2020-12/31/2023). Medicaid-insured adults with schizophrenia or BD-I with ≥1 OLZ/SAM or olanzapine claim were eligible; OLZ/SAM claims were prioritized over olanzapine claims to set the index date. Patients were propensity score matched 1:1 on baseline demographic/clinical variables between the OLZ/SAM and olanzapine cohorts. Treatment patterns (adherence, persistence, discontinuation), inpatient (IP) admissions, and emergency department (ED) visits (all cause, mental health related, or disease related [used as proxies for relapse]) were compared between cohorts during 12-month follow-up.
Results: After matching, 1614 patients with schizophrenia (OLZ/SAM, n=807; olanzapine, n=807) and 1008 with BD-I (OLZ/SAM, n=504; olanzapine, n=504) were included across both treatment cohorts. In both cohorts, OLZ/SAM was associated with significantly higher adherence, longer persistence, and lower discontinuation rates versus olanzapine. OLZ/SAM was associated with significantly lower likelihood of ≥1 all-cause, mental health-related, or disease-related IP admission (odds ratio [OR] ranges, schizophrenia: 0.52-0.59; BD-I: 0.52-0.58) or ED visit (OR ranges, schizophrenia: 0.47-0.54; BD-I: 0.62-0.74).
Conclusions: OLZ/SAM treatment offers real-world effectiveness benefits over olanzapine, with favorable treatment patterns and significantly lower likelihood of acute care events. Significantly lower likelihood of disease-related acute care events suggests lower relapse risk with OLZ/SAM treatment.
Short Description: This claims analysis compared combined olanzapine and samidorphan (OLZ/SAM) with olanzapine in Medicaid‑insured adults with schizophrenia or bipolar I disorder. OLZ/SAM was associated with higher adherence and persistence and lower discontinuation versus olanzapine and significantly fewer inpatient admissions and emergency department visits across all‑cause, mental health-related, and disease‑related categories. OLZ/SAM treatment offers meaningful real-world effectiveness benefits over olanzapine, as observed by favorable treatment patterns and significantly lower likelihood of acute care events.
Name of Sponsoring Organization(s): This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
